News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
217–252
Matches
1153
Sources here
20
Companies here
19
Search results Stored financial headlines

Active search

1153 matching headlines

Ticker or company: HYMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Hydrofarm Holdings (HYFM) President reports 740-share tax withholding on RSU vesting

Hydrofarm Holdings (HYFM) President Mark S. Parker reported a tax-related disposition where 740 shares of common stock were withheld at $1.60 per share. This was to satisfy a tax withholding obligation stemming from the vesting of 1,667 stock-settled restricted stock units. Following this transaction, …

HYFM main company
Sharemaestro market context Price above Trend Line 52 weeks -66.4% · Next-week setup negative 39.5% HYFM stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Hydrofarm (HYFM) CAO Erica Ackerman logs 138-share tax withholding event

Hydrofarm Holdings Group, Inc.'s CAO, Erica Ackerman, reported a tax withholding event on August 8, 2026, involving 138 shares of common stock. These shares, valued at $1.60 each, were withheld to cover tax obligations from the vesting of 334 stock-settled restricted stock units. After …

HYFM main company
Sharemaestro market context Price above Trend Line 52 weeks -66.4% · Next-week setup negative 39.5% HYFM stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Rhythm Pharmaceuticals (RYTM) insider outlines 10b5-1 stock sale plan in Form 144

A Rhythm Pharmaceuticals insider, Pamela Cramer, has filed a Form 144 detailing planned sales of company common stock through a 10b5-1 plan via Morgan Stanley Smith Barney LLC. The filing includes shares from stock option exercises and restricted stock units, alongside a previous sale …

RYTM main company
Sharemaestro market context Trend signal active 52 weeks +11.8% RYTM stored weekly price path from 22 Aug 2025 to 14 Aug 2026

iRhythm edges lower amid Spruce Point short comments

[Doctor and patient in conversation, looking at digital tablet] Solskin * iRhythm (IRTC [https://seekingalpha.com/symbol/IRTC]) ticked lower by 2% amid comments from Spruce Point Research. * iRhythm (IRTC [https://seekingalpha.com/symbol/IRTC]) didn't immediately respond to Seeking Alpha's email request for comment. * Spruce Point first issued a …

IRTC main company
Sharemaestro market context Price above Trend Line 52 weeks -25.2% IRTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Murphy Oil drills Lac Da Trang prospect offshore Vietnam

Murphy Oil has spud the Lac Da Trang North-1X exploration well offshore Vietnam, targeting 40 MMbbl to 80 MMbbl of recoverable resources. This prospect could be developed as a tieback to the company's Lac Da Vang project, which is on track for first oil …

MUR main company
Sharemaestro market context Price below Trend Line 52 weeks +48.1% MUR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Thyssenkrupp nucera AG & Co. KGaA: SOEC-Neuausrichtung führt zu Anpassung der EBIT-Prognose 2025/26; Aktualisierung der Auftragseingangs- und Umsatz-Erwartung auf Basis bisheriger Geschäftsentwicklung

NCH2 main company
Sharemaestro market context Price below Trend Line 52 weeks -14.9% NCH2 stored weekly price path from 22 Aug 2025 to 14 Aug 2026

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: SOEC-Neuausrichtung führt zu Anpassung der EBIT-Prognose 2025/26; Aktualisierung der Auftragseingangs- und Umsatz-Erwartung auf Basis bisheriger Geschäftsentwicklung - boerse.de

NCH2 main company
Sharemaestro market context Price below Trend Line 52 weeks -14.6% NCH2 stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Algorhythm Holdings to report Q2 results

Algorhythm Holdings is scheduled to release its second-quarter 2026 financial results on August 14, 2026. This news brief was generated by Public Technologies using AI and is based on original content published by Algorhythm Holdings Inc. via GlobeNewswire. The information is for informational purposes …

RIME main company
Sharemaestro market context Price below Trend Line 52 weeks -81.5% · Next-week setup negative 36.4% RIME stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Algorhythm Holdings sets a date to share June-quarter results

Algorhythm Holdings (NASDAQ:RIME) announced it will release its financial results for the second quarter ended June 30, 2026, on Friday, August 14, 2026. The AI-powered logistics solutions provider shared this information from Fort Lauderdale, Florida. Prior comparable earnings-date events for the company have averaged …

RIME main company
Sharemaestro market context Price below Trend Line 52 weeks -81.5% · Next-week setup negative 36.4% RIME stored weekly price path from 22 Aug 2025 to 14 Aug 2026

SK Hynix Has Suffered Post-IPO as Memory Flags: A Wall Street Pro Remains Sanguine With 160% Returns Predicted

Quick Read SK Hynix dropped 20% post-IPO from $168 to $135 as a broader AI selloff triggered limit-down trading in South Korea's Nextrade system. Macquarie's Daniel Kim sets a Street-high $355 target on SKHY, implying 162% upside from its near-monopoly position supplying NVDA's AI …

SKHY main company
Sharemaestro market context Stored weekly price path 6 weeks -1.0% · Next-week setup negative 23.7% SKHY stored weekly price path from 10 Jul 2026 to 14 Aug 2026

Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

Rhythm Pharmaceuticals, Inc. -- MHRA grants authorization for patients 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment -- BOSTON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused …

RYTM main company
Sharemaestro market context Trend signal active 52 weeks +11.8% RYTM stored weekly price path from 22 Aug 2025 to 14 Aug 2026

SKHY Reportedly Revives China NAND Plant After 4-Year Pause, Days After $39B Korean Fabs Investment

SK Hynix (SKHY) is reportedly restarting construction at its NAND plant in Dalian, China, after a four-year pause, aiming to add 50,000 wafers per month to its NAND capacity by mid-2027. This move follows a recent announcement of a $39 billion investment in two …

SKHY main company
Sharemaestro market context Stored weekly price path 6 weeks -1.0% · Next-week setup negative 23.7% SKHY stored weekly price path from 10 Jul 2026 to 14 Aug 2026

iRhythm Technologies $IRTC Shares Acquired by Quantinno Capital Management LP

Quantinno Capital Management LP significantly increased its stake in iRhythm Technologies (NASDAQ:IRTC) by 1,172.8% in the first quarter, now owning 18,621 shares valued at approximately $2.2 million. The company reported strong financial results, with quarterly revenue up 20.1% year over year to $224.17 million …

IRTC main company
Sharemaestro market context Price above Trend Line 52 weeks -25.2% IRTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026

The Technical Signals Behind (IRTC) That Institutions Follow

This article provides a technical analysis of Irhythm Technologies Inc. (NASDAQ: IRTC), detailing institutional trading strategies based on AI models. It identifies strong near- and mid-term sentiment but a weak long-term outlook, with key support and resistance levels. The analysis also highlights a significant …

IRTC main company
Sharemaestro market context Price above Trend Line 52 weeks -25.2% IRTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Rhythm Pharmaceuticals (NASDAQ:RYTM) has received a "Moderate Buy" consensus recommendation from brokerages, with 15 out of 18 analysts rating the stock as a buy. The average 12-month price target is $142.44, exceeding the current share price of $115.48. The company reported strong quarterly revenue …

RYTM main company
Sharemaestro market context Trend signal active 52 weeks +11.8% RYTM stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Intercontinental Hotels Group H1 Earnings Call Highlights

Key Points Interested in Intercontinental Hotels Group? Here are five stocks we like better. Strong first-half financial performance: Global RevPAR rose 4.1%, fee revenue increased 7%, operating profit grew 10%, and adjusted EPS climbed 13% to 274.7 cents. IHG raised its interim dividend 10% …

H main company
Sharemaestro market context Trend signal active 52 weeks +26.1% H stored weekly price path from 22 Aug 2025 to 14 Aug 2026

SK hynix Commits $37B to New Yongin, Cheongju Fabs for AI Memory Growth

SK hynix has approved an investment of approximately $37 billion to construct two new semiconductor fabs in South Korea. This strategic expansion in Yongin and Cheongju aims to bolster its production capacity for DRAM and NAND memory, driven by the increasing demand from AI …

SKHY main company
Sharemaestro market context Stored weekly price path 6 weeks -1.0% · Next-week setup negative 23.7% SKHY stored weekly price path from 10 Jul 2026 to 14 Aug 2026

(HY) Movement Within Algorithmic Entry Frameworks

This article provides an algorithmic analysis of Hyster-Yale Materials Handling Inc. (NYSE: HY), highlighting strong near and mid-term positive sentiment and a test of support. It outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. …

HY main company
Sharemaestro market context Price below Trend Line 52 weeks -8.0% HY stored weekly price path from 22 Aug 2025 to 14 Aug 2026

RHYTHM PHARMACEUTICALS, INC. SEC Filing (Aug 10, 2026)

This article details an SEC Form 144 filing by RHYTHM PHARMACEUTICALS, INC. (RYTM) on August 10, 2026. The filing indicates a proposed sale of 3,520 common shares with an aggregate market value of $407,017.60, acquired through the exercise of stock options on the same …

RYTM main company
Sharemaestro market context Trend signal active 52 weeks +11.8% RYTM stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Why iRhythm (IRTC) Stock Is Trading Up Today

Why iRhythm (IRTC) Stock Is Trading Up Today What Happened? Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC) jumped 2% in the afternoon session after the company reported strong second-quarter financial results that surpassed expectations and raised its full-year guidance. The cardiac monitoring company …

IRTC main company
Sharemaestro market context Price above Trend Line 52 weeks -25.2% IRTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026

U.S. Physical Therapy, Inc. (NYSE:USPH) Given Consensus Recommendation of "Moderate Buy" by Brokerages

U.S. Physical Therapy, Inc. (NYSE:USPH) has received a consensus "Moderate Buy" rating from seven brokerages, with an average 12-month price target of $97.50 against its current price of $79.89. The company's latest quarterly results showed an 8.5% year-over-year revenue increase to $214.06 million, though …

USPH main company
Sharemaestro market context Price above Trend Line 52 weeks -5.2% USPH stored weekly price path from 22 Aug 2025 to 14 Aug 2026

iRhythm Technologies (NASDAQ:IRTC) Stock Price Expected to Rise, Truist Financial Analyst Says

Truist Financial has increased its price target for iRhythm Technologies (NASDAQ:IRTC) from $160 to $168, maintaining a "buy" rating and indicating a potential upside of 34.59%. This positive outlook aligns with a "Moderate Buy" consensus rating from MarketBeat analysts, despite some recent target reductions …

IRTC main company
Sharemaestro market context Price above Trend Line 52 weeks -25.2% IRTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026

RYTM - High-Growth Emerging Commercial Stage Biotech

Rhythm Pharmaceuticals (RYTM) is presented as a high-growth commercial-stage biotech company focused on orphan neuroendocrine disorders, particularly those related to MC4R pathway dysfunction (genetic obesity). The article highlights the company's strong Q2 2026 results for IMCIVREE, with better-than-expected patient uptake and international growth, along …

RYTM main company
Sharemaestro market context Trend signal active 52 weeks +11.8% RYTM stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Hypoport Q2 Earnings Call Highlights

Key Points Interested in Hypoport SE? Here are five stocks we like better. Mortgage outlook remains broadly stable: Hypoport's full-year EBIT guidance assumes a potential market impact ranging from negative €2 million to positive €10 million, based on a flat-to-single-digit-growth German mortgage market. Europace …

HYQ main company HYQ main company
Sharemaestro market context Price above Trend Line 52 weeks -43.6% HYQ stored weekly price path from 22 Aug 2025 to 14 Aug 2026

IRhythm to Gain From VitalConnect Deal, Rising Margins, Oppenheimer Says

Oppenheimer expects iRhythm Technologies to benefit from its acquisition of VitalConnect, which will add a significant product to its portfolio and is expected to be immediately accretive to margins. The firm reiterates an Outperform rating and a $170 price target for iRhythm, citing potential …

IRTC main company
Sharemaestro market context Price above Trend Line 52 weeks -25.2% IRTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026

US PHYSICAL THERAPY INC : BARRINGTON RESEARCH RAISES TARGET PRICE TO $98 FROM $90

Barrington Research has increased its target price for US PHYSICAL THERAPY INC (USPH.N) to $98, up from the previous $90. This adjustment reflects the analyst's updated outlook on the company's valuation. The report was published by Reuters on August 10, 2026.

USPH main company
Sharemaestro market context Price above Trend Line 52 weeks -5.2% USPH stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context